Estimation of glomerular filtration rate in patients with abnormal body composition and relation with carboplatin toxicity

Date

09 Oct 2016

Session

Poster display

Presenters

Marie Bretagne

Citation

Annals of Oncology (2016) 27 (6): 497-521. 10.1093/annonc/mdw390

Authors

M. Bretagne, A. Jouinot, J. Durand, C. Tlemsani, J. Arrondeau, O. Huillard, P. Boudou Rouquette, F. Goldwasser, J. Alexandre

Author affiliations

  • Department Of Medical Oncology, Cochin Hospital, Paris Descartes University, Ap­hp, Carpem, Certim, Hôpital Cochin, 75014 - Paris/FR
More

Resources

Background

Carboplatin clearance is correlated with Glomerular Filtration Rate (GFR), which is usually evaluated with creatinine clearance using Cockcroft-Gault (CG) formula. Because serum creatinine (sCR) level is related to total muscle mass, we hypothesized that an abnormal body composition with a low lean body mass (LBM) percentage (LBM / weight) may result in GFR overestimation and inadequate carboplatin dose calculation by using CG formula. Serum cystatin C (sCY) is an alternative marker of GFR which is not affected by muscle mass. We aimed to correlate GFR creatinine (GFRCr) and cystatin C (GFRCy) to LBM percentage and the risk of toxicity. A high GFRCr/GFRCy ratio might estimate the miscalculation of GFR with sCR.

Methods

sCR and sCY were prospectively measured in consecutive cancer patients (pts) before chemotherapy. GFRCr and GFRCy were calculated with CG and GRUBB formula, respectively. The LBM was assessed using CT-scan. Febrile neutropenia and grade 3-4 thrombocytopenia were analysed in a subgroup of pts treated with carboplatin AUC 5 +/- paclitaxel.

Results

In 134 cancer pts (males 51%), median age was 63.7 (20 – 89). In 128 pts without severe renal insufficiency, sCR was correlated with LBM (r = 0.30, Pearson correlation coefficient, p  1.4.

Conclusions

Pts with a low LBM percentage (sarcopenic overweight pts) are at high risk of inadequate calculation of renal function, over dosage of carboplatin and increased acute limiting toxicity. High GFRCr/GFRCy ratio allows to identify these pts.

Clinical trial identification

Legal entity responsible for the study

J. Alexandre

Funding

Fondation Martine Midy

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings